cell therapy
-
Biologics
Bone Therapeutics to strategically focus on lead cell therapy product ALLOB
REGULATED INFORMATION Strategic focus revised and fully focused on achieving topline results of the ALLOB Phase IIb study in tibial…
Read More » -
Biologics
DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone
SALT LAKE CITY and TOKYO, April 27, 2021 /PRNewswire/ — DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate…
Read More » -
Biologics
DiscGenics Announces Completion of Enrollment in U.S. Phase 1/2 Clinical Trial of Discogenic Cell Therapy for Degenerative Disc Disease
SALT LAKE CITY, March 4, 2020 /PRNewswire/ — DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate…
Read More » -
Biologics
DiscGenics’ U.S. Clinical Study of Cell Therapy for Disc Degeneration Passes Halfway Mark
SALT LAKE CITY, Sept. 16, 2019 /PRNewswire/ —DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate…
Read More » -
Spine
DiscGenics Announces First Patients Treated in Japanese Clinical Trial of Cell Therapy for Degenerative Disc Disease
SALT LAKE CITY, Aug. 7, 2019 /PRNewswire/ — DiscGenics, Inc., a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate…
Read More » -
Biologics
SpinalCyte, LLC Announces New Results from Phase II Animal Trials of Cell Therapy to Regenerate the Spinal Disc
HOUSTON–(BUSINESS WIRE)–SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using Human Dermal…
Read More » -
Biologics
Bone Therapeutics Expands Its Delayed-Union Program with ALLOB® into Multiple Fractures
GOSSELIES, Belgium–(BUSINESS WIRE)–Regulatory News: BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE), the bone cell therapy company addressing high unmet medical needs in the field…
Read More » -
Biologics
Bone Therapeutics: ALLOB® Delayed-Union Program Awarded at Cells Orthopedics Conference
BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair…
Read More » -
Financial
Bone Therapeutics Awarded EUR 3 million in Funding to Support New Research Projects
GOSSELIES, Belgium–(BUSINESS WIRE)–Regulatory News: BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of…
Read More » -
Biologics
Pluristem & Charite Expand Cooperation Agreement to Include Orthopedic Indications
HAIFA, Israel, Oct. 12, 2015 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products,…
Read More » -
Biologics
Histogenics Corporation and Collagen Solutions plc Establish Supply Agreement
WALTHAM, Mass., Sept. 16, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing…
Read More » -
Biologics
Aastrom Announces Strategic Plan for Recently Acquired Cell Therapy and Regenerative Medicine Business
Manufacturing of MACI in Denmark to be discontinued Sales of MACI in Europe, representing 1% of revenues in 2014, temporarily…
Read More »